PerkinElmer is a diagnostics & research business based in the US. PerkinElmer shares (PKI) are listed on the NYSE and all prices are listed in US Dollars. PerkinElmer employs 16,700 staff and has a trailing 12-month revenue of around $3.3 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $127.44 |
| 200-day moving average | $131.99 |
| Wall St. target price | $149.71 |
| PE ratio | 41.4532 |
| Dividend yield | $0.28 (0.24%) |
| Earnings per share (TTM) | $2.78 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing PerkinElmer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PerkinElmer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PerkinElmer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, PerkinElmer shares trade at around 41x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
PerkinElmer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.0183. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PerkinElmer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PerkinElmer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 billion.
The EBITDA is a measure of a PerkinElmer's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $3.3 billion |
|---|---|
| Operating margin TTM | 25.96% |
| Gross profit TTM | $2 billion |
| Return on assets TTM | 3.69% |
| Return on equity TTM | 7.06% |
| Profit margin | 17.19% |
| Book value | $58.46 |
| Market Capitalization | $14.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 4.28% of net profits
Recently PerkinElmer has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), PerkinElmer shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In PerkinElmer's case, that would currently equate to about $0.28 per share.
While PerkinElmer's payout ratio might seem low, this can signify that PerkinElmer is investing more in its future growth.
PerkinElmer's most recent dividend payout was on 10 August 2023. The latest dividend was paid out to all shareholders who bought their shares by 19 July 2023 (the "ex-dividend date").
PerkinElmer's shares were split on a 2:1 basis on 3 June 2001 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your PerkinElmer shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for PerkinElmer shares which in turn could have impacted PerkinElmer's share price.
Over the last 12 months, PerkinElmer's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while PerkinElmer's is 1.1013. This would suggest that PerkinElmer's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.